HighTower Advisors LLC Trims Stock Holdings in 10x Genomics $TXG

HighTower Advisors LLC reduced its stake in 10x Genomics (NASDAQ:TXG) by 39.3% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 11,180 shares of the company’s stock after selling 7,252 shares during the period. HighTower Advisors LLC’s holdings in 10x Genomics were worth $98,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. GAMMA Investing LLC grew its stake in shares of 10x Genomics by 81.8% in the first quarter. GAMMA Investing LLC now owns 3,586 shares of the company’s stock valued at $31,000 after buying an additional 1,614 shares in the last quarter. Deutsche Bank AG boosted its holdings in 10x Genomics by 35.3% in the fourth quarter. Deutsche Bank AG now owns 10,190 shares of the company’s stock valued at $146,000 after purchasing an additional 2,657 shares during the period. Cetera Investment Advisers boosted its holdings in 10x Genomics by 22.7% in the fourth quarter. Cetera Investment Advisers now owns 19,898 shares of the company’s stock valued at $286,000 after purchasing an additional 3,679 shares during the period. Rhumbline Advisers boosted its holdings in 10x Genomics by 11.4% in the first quarter. Rhumbline Advisers now owns 120,490 shares of the company’s stock valued at $1,052,000 after purchasing an additional 12,374 shares during the period. Finally, Gotham Asset Management LLC purchased a new position in 10x Genomics in the fourth quarter valued at $264,000. 84.68% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Canaccord Genuity Group set a $16.00 price objective on 10x Genomics in a research report on Monday, August 11th. Morgan Stanley lowered their price objective on 10x Genomics from $18.00 to $17.00 and set an “overweight” rating for the company in a research report on Tuesday, August 12th. Bank of America boosted their price objective on 10x Genomics from $12.00 to $13.00 and gave the stock a “neutral” rating in a research report on Thursday, June 26th. Stephens reissued an “overweight” rating and set a $14.00 price objective on shares of 10x Genomics in a research report on Thursday, May 15th. Finally, Barclays reissued an “overweight” rating and set a $15.00 price objective (up from $13.00) on shares of 10x Genomics in a research report on Friday, August 8th. Six investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, 10x Genomics currently has an average rating of “Hold” and an average target price of $13.54.

Insider Activity

In other news, CFO Adam Taich sold 22,315 shares of the stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $307,723.85. Following the completion of the sale, the chief financial officer directly owned 309,273 shares of the company’s stock, valued at approximately $4,264,874.67. This represents a 6.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Benjamin J. Hindson sold 7,486 shares of the stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total value of $103,231.94. Following the completion of the sale, the insider directly owned 440,888 shares of the company’s stock, valued at $6,079,845.52. The trade was a 1.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 39,149 shares of company stock valued at $539,865. Insiders own 9.39% of the company’s stock.

10x Genomics Price Performance

Shares of NASDAQ TXG opened at $13.96 on Friday. The company has a market capitalization of $1.74 billion, a price-to-earnings ratio of -19.94 and a beta of 2.00. The business has a 50-day moving average of $13.15 and a two-hundred day moving average of $10.75. 10x Genomics has a 1 year low of $6.78 and a 1 year high of $24.38.

10x Genomics (NASDAQ:TXG) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.63. The company had revenue of $172.91 million during the quarter, compared to the consensus estimate of $139.36 million. 10x Genomics had a negative return on equity of 12.88% and a negative net margin of 13.13%.10x Genomics’s revenue for the quarter was up 12.9% on a year-over-year basis. During the same period in the previous year, the business earned ($0.32) EPS. 10x Genomics has set its Q3 2025 guidance at EPS. As a group, equities research analysts expect that 10x Genomics will post -1.43 earnings per share for the current year.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.